Search Medical Condition
Please enter condition
Please choose location from dropdown

Jonan-Ku, Fukuoka-Shi, Japan Clinical Trials

A listing of Jonan-Ku, Fukuoka-Shi, Japan clinical trials actively recruiting patients volunteers.

RESULTS

Found (193) clinical trials

A Study Of Avelumab In Combination With Axitinib In Advanced HCC (VEGF Liver 100)

To evaluate the safety, efficacy and PK of avelumab in combination with axitinib as first line treatment in patients with advanced HCC

Phase

1.26 miles

Learn More »

A Study of Molidustat for Maintenance Treatment of Renal Anemia in Non-dialysis Subjects

The purpose of this study is to evaluate the efficacy and safety of molidustat in non-dialysis subjects previously treated with Erythropoiesis-Stimulating Agents (ESAs)

Phase

1.26 miles

Learn More »

Study of Durvalumab and Tremelimumab as First-line Treatment in Patients With Unresectable Hepatocellular Carcinoma

The study population includes patients 18 years of age or older with unresectable HCC, Barcelona Clinic Liver Cancer stage B not eligible for locoregional therapy or stage C, and Child-Pugh A classification liver disease. Patients must not have received any prior systemic therapy for unresectable HCC. Patients in all treatment ...

Phase

1.26 miles

Learn More »

Double Blind Placebo Controlled Controlled Study of Adjuvant MEDI4736 In Completely Resected NSCLC

The purpose of this study is to find out whether it is better to receive a new drug, MEDI4736, or better to receive no further treatment after surgery (and possibly chemotherapy) for lung cancer.

Phase

1.26 miles

Learn More »

A Study to Evaluate the Effect of Dapagliflozin on Renal Outcomes and Cardiovascular Mortality in Patients With Chronic Kidney Disease

This is an international, multicentre, event-driven, randomized, double-blind, parallel group, placebo-controlled study, evaluating the effect of dapagliflozin versus placebo, given once daily in addition to standard of care, to prevent the progression of chronic kidney disease (CKD) or cardiovascular (CV)/renal death.

Phase

1.42 miles

Learn More »

A Study of Duloxetine (LY248686) in the Treatment of Japanese Children and Adolescents With Depressive Disorder

The purpose of this long-term study is to evaluate the safety and efficacy of duloxetine hydrochloride in Japanese children and adolescents with depressive disorder.

Phase

1.72 miles

Learn More »

A Study of Duloxetine (LY248686) in Japanese Children and Adolescents With Depressive Disorder

The purpose of this study is to determine the efficacy of duloxetine hydrochloride versus placebo in the treatment of Japanese children and adolescents with depressive disorder.

Phase

1.72 miles

Learn More »

Japanese Idiopathic Interstitial Pneumonias Registry

JIPS Registry is a multi-site, non-interventional, prospective observation study of patients with newly diagnosed IIPs in Japan. At least 600 patients will be registered for 16 months at approximately 80 sites in Japan. Primary research question is to determine the natural history of each category of IIPs at registration, patient ...

Phase N/A

1.76 miles

Learn More »

Study to Evaluate the Antiviral Activity Clinical Outcomes Safety Tolerability and Pharmacokinetics of Orally Administered Lumicitabine Regimens in Adult Participants Hospitalized With Respiratory Syncytial Virus

The study will be conducted in 3 phases: a screening phase, a treatment phase from Day 1 to Day 5/6 (depending on the timing of the loading dose), and a follow-up phase for a total of 28 days post randomization. Participants will have assessments completed at Day 7, Day 10, ...

Phase

1.76 miles

Learn More »

221AD302 Phase 3 Study of Aducanumab (BIIB037) in Early Alzheimer's Disease

The primary objective of the study is to evaluate the efficacy of monthly doses of aducanumab in slowing cognitive and functional impairment as measured by changes in the Clinical Dementia Rating-Sum of Boxes (CDR-SB) score as compared with placebo in participants with early AD. Secondary objectives are to assess the ...

Phase

1.76 miles

Learn More »